Edition:
India

Kyowa Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,866JPY
3 Dec 2020
Change (% chg)

¥-16 (-0.56%)
Prev Close
¥2,882
Open
¥2,899
Day's High
¥2,902
Day's Low
¥2,866
Volume
679,600
Avg. Vol
752,459
52-wk High
¥3,060
52-wk Low
¥1,849

Latest Key Developments (Source: Significant Developments)

Kura Oncology Appoints Dr. Stephen Dale As Chief Medical Officer
Tuesday, 25 Aug 2020 

Aug 25 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY APPOINTS DR. STEPHEN DALE AS CHIEF MEDICAL OFFICER.KURA ONCOLOGY APPOINTS DR. STEPHEN DALE AS CHIEF MEDICAL OFFICER.KURA ONCOLOGY INC - STEPHEN DALE JOINS KURA MOST RECENTLY FROM KYOWA KIRIN.  Full Article

Mei Pharma And Kyowa Kirin Announce Updated Clinical Data From Early-Stage Follicular Lymphoma Study
Thursday, 14 May 2020 

May 13 (Reuters) - Kyowa Kirin Co Ltd <4151.T>::MEI PHARMA AND KYOWA KIRIN ANNOUNCE UPDATED CLINICAL DATA FROM THE PHASE 1B STUDY EVALUATING ME-401 ON AN INTERMITTENT SCHEDULE IN PATIENTS WITH FOLLICULAR LYMPHOMA AND OTHER B-CELL MALIGNANCIES; DATA TO BE FEATURED IN THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2020 VIRTUAL SCIENTIFIC PROGRAM.MEI PHARMA INC - 83% OVERALL RESPONSE RATE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.MEI PHARMA INC - ME-401 REMAINS GENERALLY WELL-TOLERATED WITH 7% DISCONTINUATION RATE DUE TO ADVERSE EVENTS IN THIS STUDY.  Full Article

Ultragenyx And Kyowa Kirin Announce FDA Acceptance And Priority Review Designation Of Supplemental Biologics License Application For Crysvita
Thursday, 27 Feb 2020 

Feb 27 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR CRYSVITA® (BUROSUMAB) FOR TUMOR-INDUCED OSTEOMALACIA (TIO).ULTRAGENYX PHARMACEUTICAL - FDA ASSIGNED PRIORITY REVIEW DESIGNATION WITH PDUFA TARGET DATE OF JUNE 18, 2020.  Full Article

Ultragenyx And Kyowa Kirin Submit Supplemental Biologics License Application To FDA For Crysvita®
Monday, 13 Jan 2020 

Jan 13 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA KIRIN ANNOUNCE SUBMISSION OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO U.S. FDA FOR CRYSVITA® (BUROSUMAB) FOR TUMOR-INDUCED OSTEOMALACIA (TIO).ULTRAGENYX PHARMACEUTICAL - CO, KYOWA KIRIN EXPECT TO HEAR BACK FROM FDA ON SUBMISSION ACCEPTANCE AND REVIEW DESIGNATION IN FEBRUARY 2020.  Full Article

Ardelyx And Kyowa Kirin Expand Partnership With Two Additional Agreements
Tuesday, 26 Nov 2019 

Nov 25 (Reuters) - Kyowa Kirin Co Ltd <4151.T>::ARDELYX AND KYOWA KIRIN EXPAND PARTNERSHIP WITH TWO ADDITIONAL AGREEMENTS.ARDELYX - ESTABLISH RESEARCH COLLABORATION TO LICENSE RESULTING DEVELOPMENT CANDIDATES WITH POTENTIAL FOR UP TO $500 MILLION IN SALES MILESTONES FOR CO.ARDELYX - KYOWA KIRIN MAKES $20 MILLION EQUITY INVESTMENT IN ARDELYX.ARDELYX - IN FIRST AGREEMENT KYOWA KIRIN WILL PAY CO $10 MILLION TO SUPPORT RESEARCH ON IDENTIFICATION, DESIGN OF COMPOUNDS TO 2 UNDISCLOSED TARGETS.  Full Article

Kyowa Kirin Inc Says Nourianz (Istradefylline) Now Available In U.S. For Treatment Of Parkinson's Disease "Off" Episodes
Tuesday, 15 Oct 2019 

Oct 14 (Reuters) - Kyowa Kirin Inc::KYOWA KIRIN ANNOUNCES NOURIANZ (ISTRADEFYLLINE) NOW AVAILABLE IN THE U.S. FOR TREATMENT OF PARKINSON'S DISEASE "OFF" EPISODES.  Full Article

Ultragenyx And Kyowa Kirin Announce Intent To Submit Supplemental Biologics License Application To U.S. FDA For Crysvita In Tumor-Induced Osteomalacia
Tuesday, 10 Sep 2019 

Sept 10 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA KIRIN ANNOUNCE INTENT TO SUBMIT SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO U.S. FDA FOR CRYSVITA® (BUROSUMAB) IN TUMOR-INDUCED OSTEOMALACIA (TIO).ULTRAGENYX - DECISION TO SUBMIT SBLA FOR CRYSVITA FOLLOWS COMPLETION OF PRE-SBLA MEETING WITH FDA AND AGREEMENT ON FILING PACKAGE.ULTRAGENYX PHARMACEUTICAL - SUBMISSION OF CRYSVITA SBLA IS PLANNED FOR FIRST HALF OF 2020 AND WILL BE BASED ON CURRENT CLINICAL DATA PACKAGE.  Full Article

Kyowa Hakko Kirin Co Announces Results Of Early Retirement Offer
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Japan's Kyowa Hakko Kirin Co Ltd <4151.T>::ANNOUNCES RESULTS OF EARLY RETIREMENT OFFER.296 EMPLOYEES ACCEPTED OFFER TO RETIRE VOLUNTARILY EFFECTIVE JUNE 30.SEVERANCE AND OUTPLACEMENT EXPENSES TO BE ABOUT 5.1 BILLION YEN, RECORDED AS 'OTHER EXPENSES' IN Q1.CONSOLIDATED FORECASTS REMAIN UNCHANGED.  Full Article

Kyowa Kirin Announces FDA Acceptance Of Istradefylline (KW-6002) New Drug Application Resubmission In The US
Thursday, 4 Apr 2019 

April 4 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::KYOWA KIRIN ANNOUNCES FDA ACCEPTANCE OF ISTRADEFYLLINE (KW-6002) NEW DRUG APPLICATION RESUBMISSION IN THE US.KYOWA HAKKO KIRIN CO LTD - TARGET PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR A DECISION BY FDA IS IN AUGUST 27, 2019..  Full Article

Kyowa Hakko Kirin To Buy Back, Cancel Shares
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::TO BUY BACK UP TO 10.7 MILLION SHARES AT 2,111 YEN EACH BEFORE MARKET OPEN WEDS.TO CANCEL THOSE SHARES AND ADDITIONAL 25.78 MILLION SHARES FEB 19.  Full Article

Japan's Kirin, hit by virus, says helped by expansion beyond beer

TOKYO Japan's Kirin Holdings cut its full-year profit outlook on Friday as the coronavirus pandemic hit global sales of its beer, but said its expansion into new businesses such as healthcare sheltered it from a bigger impact.